On June 12, 2025, Indaptus Therapeutics, Inc. entered into agreements for a private placement of $2.3 million in convertible promissory notes and warrants to fund R&D, including a clinical trial. The notes will mature on July 28, 2026, and the proceeds will also support working capital and general corporate purposes.